Molecular Formula | C17H18N4O3S |
Molar Mass | 358.41 |
Density | 1.462±0.06 g/cm3(Predicted) |
Boling Point | 623.8±65.0 °C(Predicted) |
pKa | 2.40±0.10(Predicted) |
Storage Condition | -20°C,密闭,干燥 |
Use | MC180295 ((rel)-MC180295) is a potent, selective CDK9-Cyclin T1 inhibitor with an IC50 value of 5 nM and is at least 22-fold selective for other CDK kinases. MC18029 |
In vitro study | MC180295 has a wide range of anticancer activity in vitro. |
In vivo study | MC180295 has Anti tumor and immune allergic activity. |
biological activity | MC180295 ((rel)-MC180295) is a new and effective selective CDK9 inhibitor with IC50 of 5 nM, and its selectivity to CDK9 is at least 22 times higher than that of other CDKs. |
target | TargetValue CDK9-Cyclin T1 (Cell-Free Assay) 5 nM CDK4-Cyclin D (Cell-Free Assay) 112 nM CDK1-Cyclin B (Cell-Free Assay) 138 nM CDK5-P35 (Cell-Free Assay) 159 nM CDK5-P25 (Cell-Free Assay) 186 nM |
Target | Value |
CDK9-Cyclin T1 (Cell-free assay) | 5 nM |
CDK4-Cyclin D (Cell-free assay) | 112 nM |
CDK1-Cyclin B (Cell-free assay) | 138 nM |
CDK5-P35 (Cell-free assay) | 159 nM |
CDK5-P25 (Cell-free assay) | 186 nM |
in vitro study | MC180295 have a wide range of anti-cancer activities in vitro. |
in vivo research | MC180295 have anti-tumor and immune allergic activities. |